RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:97292

Cardiogenic shock

high confidenceDisorder

Publications

53,113

99.2th percentile

Trials

125

Interventional, condition-specific

Researchers

1,342

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare, cardiac condition characterized by severely decreased cardiac output, hypoperfusion and end-organ dysfunction, in the presence of adequate intravascular volume. The clinical presentation is variable and may range from subtle hemodynamic alterations to overt cardiovascular collapse. Commonly reported features include dyspnea, crackles, elevated jugular venous pressure, altered mental state, abnormal pulse pressure, oliguria, cold extremities, and increased serum lactate levels.

How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    53,113 matched papers (36,677 in last 10 years) Source

  3. Phenotype characterisedPresent

    30 HPO annotations (e.g. Hypotension; Congestive heart failure; Hypoxemia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    1 FDA · 2 EMA designations (1 FDA orphan-indication approval) — e.g. Tilarginine acetate Source

  6. Interventional trialPresent

    125 matched on ClinicalTrials.gov (52 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

30

Associated phenotypes · MONDO:0800175

  • Hypotension
  • Congestive heart failure
  • Hypoxemia
  • Increased circulating lactate concentration
  • Hepatomegaly

Showing 5 of 30 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

3

Designations · 1 with FDA orphan-indication approval

  • FDA Tilarginine acetateCardiogenic shock · 2005-04-11 · Not FDA Approved for Orphan Indication
  • EMA pyridoxalated hemoglobin polyoxyethyleneTreatment of cardiogenic shock · 02/08/2007 · PositiveEMA designation
  • EMA tilarginine acetateTreatment of cardiogenic shock · 03/11/2005 · WithdrawnEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

46 associated chemicals · 26 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Amrinone · therapeutic
  • Dobutamine · therapeutic
  • Dopamine · therapeutic
  • Epinephrine · therapeutic
  • Glucagon · therapeutic
  • Isoproterenol · therapeutic
  • Milrinone · therapeutic
  • Nitroprusside · therapeutic
  • Norepinephrine · therapeutic
  • Atenolol · marker/mechanism
  • Bupropion · marker/mechanism
  • Capecitabine · marker/mechanism

Pathways: Cytokine-cytokine receptor interaction; HIF-1 signaling pathway; FoxO signaling pathway; Peroxisome; PI3K-Akt signaling pathway; Longevity regulating pathway; Longevity regulating pathway - multiple species; Apelin signaling pathway

MyDisease.info · MONDO:0800175

Literature

Is anyone studying this?

53,113

53,113 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

53,113 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

36,677 in the last 10 years · high confidence · 99.2th percentile (publications denominator)

Phrase hits: 53,113 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,342

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Gage A4 papers · 2026

    Department of Cardiovascular Medicine, Centennial Medical Center, Nashville, TN, USA.

    Papers in Europe PMC
  2. 02
    Jentzer JC4 papers · 2026

    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

    Papers in Europe PMC
  3. 03
    Katz JN4 papers · 2026

    Leon H Charney Division of Cardiology, New York University Grossman School of Medicine, New York, NY, USA.

    Papers in Europe PMC
  4. 04
    Miller PE4 papers · 2026

    Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.

    Papers in Europe PMC
  5. 05
    Safiriyu I4 papers · 2026

    Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.

    Papers in Europe PMC
  6. 06
    Zhao J4 papers · 2026

    The First School of Clinical Medicine of Lanzhou University, 730000 Lanzhou, Gansu, China.

    Papers in Europe PMC
  7. 07
    Ali T3 papers · 2026

    Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.

    Papers in Europe PMC
  8. 08
    Aurigemma C3 papers · 2026

    Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

    Papers in Europe PMC
  9. 09
    Azamfirei L3 papers · 2026

    Anesthesiology and Intensive Care Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania; (O.E.B.); (L.A.)

    Papers in Europe PMC
  10. 10
    Bălău R3 papers · 2026

    Department of Cardiovascular Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania;

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

125

interventional trials for this specific condition

125 interventional trials matched this specific condition name; 52 currently recruiting in our sample.

Data as of 11 September 2026

125 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.8th percentile).

high confidence · 98.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

125 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

132 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 56 · after dedupe 56 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 56 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (56)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Cardiogenic shock — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Cardiogenic shock"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Cardiogenic shock"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 125 interventional · 132 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T05:09:44.508Z